GlassScriptPhysician profile
Pegah Barker
NPI 1104381060
$2,984.73
in general payments reported to CMS, 2019-2025
25 companies · $803 in 2025
The $803 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $247 · 2022: $472 · 2023: $403 · 2024: $1,060 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,266.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $386.24 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $370.26 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $310.84 | 2022-2024 | Caplyta |
| Axsome Therapeutics, INC. | $268.83 | 2023-2024 | Auvelity |
| Regeneron Healthcare Solutions, INC. | $257.97 | 2025 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $190.72 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $174.31 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $149.27 | 2021-2024 | Trintellix |
| Sun Pharmaceutical Industries INC. | $148.52 | 2025 | |
| Janssen Pharmaceuticals, INC | $129.95 | 2024 | Spravato |
| Neurocrine Biosciences, INC. | $124.58 | 2022-2024 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $68.09 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $65.10 | 2025 | Sotyktu |
| Neuronetics, INC. | $58.40 | 2023 | Neurostar Tms Therapy System |
| Revance Therapeutics, INC. | $50.21 | 2025 | Daxxify |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $42.36 | 2021 | |
| Novartis Pharmaceuticals Corporation | $32.03 | 2025 | |
| Incyte Corporation | $28.54 | 2025 | Opzelura |
| Ironshore Pharmaceuticals INC. | $24.58 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.46 | 2025 | Cabtreo, Jublia, Siliq |
| Sage Therapeutics, LLC | $20.13 | 2024 | |
| Galderma Laboratories, L.P. | $17.58 | 2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $15.50 | 2025 | Zoryve |
| Alkermes, INC. | $14.03 | 2022 | |
| Neos Therapeutics, LP | $13.23 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pegah Barker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.